Announces agreements with Nippon Kayaku, Takara Shuzo and the Institute of Microbial Chemistry to develop deoxyspergualin, a potential anticancer and immunosuppressive agent. Phase II trials with deoxyspergualin are underway at NCI and clinical trials for kidney transplantation and autoimmune disease are planned in Japan. Hoechst is conducting trials in Europe. Scientific papers on the drug were presented at the 12th International Congress of the Transplantation Society in Sydney, Australia.
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."